Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By Ackerman Allison   Klein Oliver   McDermott David F.   Wang Wei   Ibrahim Nageatte   Lawrence Donald P.   Gunturi Anasuya   Flaherty Keith T.   Hodi F. Stephen   Kefford Richard   Menzies Alexander M.   Atkins Michael B.   Long Georgina V.   Sullivan Ryan J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

Blackwell Publishing

Access to resources Recommend Favorite

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

By Chan Matthew M. K.   Haydu Lauren E.   Menzies Alexander M.   Azer Mary W. F.   Klein Oliver   Lyle Megan   Clements Arthur   Guminski Alexander   Kefford Richard F.   Long Georgina V.  

Cancer, Vol. 120, Iss. 20, 2014-10 ,pp. : 3142-3153

Blackwell Publishing

Access to resources Recommend Favorite

Emerging melanoma vaccines

By Bystryn Jean-Claude   Rudolph Jennifer L  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 2, 2005-05 ,pp. : 393-402

Informa Healthcare

Access to resources Recommend Favorite

Emerging melanoma vaccines

By Bystryn Jean-Claude  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. : 213-221

Informa Healthcare

Access to resources Recommend Favorite

Secondary tumours with BRAF-inhibitors sparked by mutations

By  

Reactions Weekly, Vol. 1, Iss. 1389, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite